ClinicalTrials.Veeva

Menu

Optimal Management of Malignant Dysphagia

McGill University logo

McGill University

Status

Terminated

Conditions

Esophageal Cancer
Malignant Dysphagia

Treatments

Procedure: Stent insertion
Radiation: Brachytherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT01366833
MalignantDysphagia

Details and patient eligibility

About

According to the Canadian Cancer Society there are approximately 1700 new cases of esophageal cancer per year in Canada. As most of these patients are diagnosed in advanced stages of the disease, 1800 deaths are estimated from this cancer annually . Progressive dysphagia is the most common presenting symptom and impacts not only the patient's quality of life but the ability to tolerate life prolonging treatments such as systemic chemotherapy.

Although there are several therapeutic modalities to alleviate malignant dysphagia including laser, photodynamic therapy and cryotherapy , the use of stents and radiotherapy are the most commonly employed. However, the optimal approach to effective, timely treatment of malignant dysphagia remains a challenge. The investigators conducted a preliminary retrospective review to investigate such palliation procedures and found that a multi-modality approach may yield the most favourable results .

Therefore, our clinical trial will examine the effectiveness of adding a single dose of brachytherapy to patients with severe dysphagia who have already been treated with a endoscopically placed self-expanding metallic stent.

Enrollment

3 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years
  • Confirmed esophageal/gastroesophageal (GEJ) cancer (Siewert Type I and Type II only) of any histology on biopsy
  • Dysphagia score ≥2
  • Stage IV cancer/Metastatic disease

Exclusion criteria

  • Expected life expectancy < 3 months
  • Inability to undergo stent insertion
  • Siewert Type III gastroesophageal cancer
  • Esophageal-Airway fistula

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

3 participants in 2 patient groups

Self-expanding stent alone
Active Comparator group
Description:
All patients in Arm A will receive self-expanding stent alone
Treatment:
Procedure: Stent insertion
Brachytherapy and Stent therapy
Experimental group
Treatment:
Radiation: Brachytherapy

Trial contacts and locations

1

Loading...

Central trial contact

Myriam Martel, RN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems